Literature DB >> 11420672

The role of tetramerization in p53 function.

P Chène1.   

Abstract

The tumour suppressor gene p53 is extensively studied for its importance in cancer. In its active conformation, p53 is tetrameric and one domain - the tetramerization domain - permits the oligomerization of this protein. Until recently, little attention was given to this domain because, in contrast to the DNA-binding domain, it is not often mutated in cancer. However, various experimental studies have shown evidence that the tetramerization domain is essential for DNA binding, protein-protein interactions, post-translational modifications, and p53 degradation. Moreover, single mutations in the tetramerization domain can inactivate the wild-type protein in a manner similar to that seen with mutations in the DNA-binding domain. Interestingly, the phenotype of several tetramerization domain mutants differs from that observed with DNA-binding domain mutants. In this review, current knowledge about the importance of the tetramerization domain to the function of p53 will be summarized.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11420672     DOI: 10.1038/sj.onc.1204373

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  80 in total

1.  Targeting protein inactivation through an oligomerization chain reaction.

Authors:  Francesco Contegno; Mario Cioce; Pier Giuseppe Pelicci; Saverio Minucci
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-12       Impact factor: 11.205

2.  The cancer-associated K351N mutation affects the ubiquitination and the translocation to mitochondria of p53 protein.

Authors:  Michela Muscolini; Elisa Montagni; Vanessa Palermo; Silvia Di Agostino; Wei Gu; Salma Abdelmoula-Souissi; Cristina Mazzoni; Giovanni Blandino; Loretta Tuosto
Journal:  J Biol Chem       Date:  2011-09-27       Impact factor: 5.157

3.  Proteins of the S100 family regulate the oligomerization of p53 tumor suppressor.

Authors:  Maria Rosario Fernandez-Fernandez; Dmitry B Veprintsev; Alan R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-21       Impact factor: 11.205

4.  ENPDA: an evolutionary structure-based de novo peptide design algorithm.

Authors:  Ignasi Belda; Sergio Madurga; Xavier Llorà; Marc Martinell; Teresa Tarragó; Mireia G Piqueras; Ernesto Nicolás; Ernest Giralt
Journal:  J Comput Aided Mol Des       Date:  2005-11-03       Impact factor: 3.686

5.  The DNA binding activity of p53 displays reaction-diffusion kinetics.

Authors:  Peter Hinow; Carl E Rogers; Christopher E Barbieri; Jennifer A Pietenpol; Anne K Kenworthy; Emmanuele DiBenedetto
Journal:  Biophys J       Date:  2006-04-07       Impact factor: 4.033

6.  Regulation of p53 localization and activity by Ubc13.

Authors:  Aaron Laine; Ivan Topisirovic; Dayong Zhai; John C Reed; Katherine L B Borden; Ze'ev Ronai
Journal:  Mol Cell Biol       Date:  2006-09-25       Impact factor: 4.272

7.  Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.

Authors:  Rui Kamada; Takao Nomura; Carl W Anderson; Kazuyasu Sakaguchi
Journal:  J Biol Chem       Date:  2010-10-26       Impact factor: 5.157

8.  Mutant p53 promotes tumor cell malignancy by both positive and negative regulation of the transforming growth factor β (TGF-β) pathway.

Authors:  Lei Ji; Jinjin Xu; Jian Liu; Ali Amjad; Kun Zhang; Qingwu Liu; Lei Zhou; Jianru Xiao; Xiaotao Li
Journal:  J Biol Chem       Date:  2015-03-12       Impact factor: 5.157

9.  p53 oligomerization status modulates cell fate decisions between growth, arrest and apoptosis.

Authors:  Nicholas W Fischer; Aaron Prodeus; David Malkin; Jean Gariépy
Journal:  Cell Cycle       Date:  2016-10-18       Impact factor: 4.534

10.  Dipeptide analysis of p53 mutations and evolution of p53 family proteins.

Authors:  Qiang Huang; Long Yu; Arnold J Levine; Ruth Nussinov; Buyong Ma
Journal:  Biochim Biophys Acta       Date:  2013-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.